Company: RGNT
Filing Date: 2025-09-30
Form Type: F-1/A
Source: 0001213900-25-093302
Chunk: 166

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-09-30
Form: F-1/A
Chunk 166
---
                                                   |

<div align='center'>99</div>

The term of office for external
directors for Israeli companies traded on certain foreign stock exchanges, including the NYSE American Rules, may be extended indefinitely
in increments of additional three-year terms, in each case provided that the audit committee and the board of directors of the company
confirm that, in light of the external director’s expertise and special contribution to the work of the board of directors and
its committees, the reelection for such additional period(s) is beneficial to the company, and provided that the external director is
reelected subject to the same requirements as if elected for the first two additional three-year terms (as described above).

External directors may be
removed from office by a special general meeting of shareholders called by the board of directors, which approves such dismissal by the
same shareholder vote percentage required for their election, after receiving the board of directors’ arguments for such removal,
or by a court, in each case, only under limited circumstances, including ceasing to meet the statutory qualifications for appointment,
or violating their duty of loyalty to the company. If an external directorship becomes vacant and there are fewer than two external directors
on the board of directors at the time, then the board of directors is required under the Companies Law to call a shareholders meeting
as soon as practicable to appoint a replacement external director.

Each committee of the board
of directors that is authorized to exercise the powers of the board of directors must include at least one external director, except
that the audit committee and the compensation committee must include all external directors then serving on the board of directors.

External directors may be
compensated only in accordance with regulations adopted under the Companies Law.

Committees of the Board of Directors

Audit Committee

We have established an audit
committee to be effective as of the effective time of the registration statement to which this prospectus relates. The members of this
committee will be Mr. Keith Valentine, Mr. Pini Ben-Elazar, and Mr. Cohen-Arazi. Mr. Cohen-Arazi will serve as the chairperson of the
committee. Each member of our audit committee will be independent as such term is defined in Rule 10A-3 under the Exchange Act, and each
member of our audit committee will satisfy the additional requirements applicable under the NYSE American Rules to members of audit committees.
Our board of directors has determined that each of Mr. Keith Valentine and Dr. Susan Alpert is an “audit committee financial expert”
as